Table 3 Overview of studies evaluating different dCRT regimens for EC
Author (year) | Number of patients | Study design | Histology | Radiotherapy | Simultaneous Chemotherapy | Median overall survival | Local failure | Distant failure | ≥ III° heamtologic toxicity |
|---|---|---|---|---|---|---|---|---|---|
Ruppert, BN (2010) [11] | 19 | Retrospective | 42% SCC | 50.4–61.2 Gy; daily dose 1.8–2 Gy | Paclitaxel Carboplatin | 1-year OS 68.4% | 42.1% | 10.5% | 46.7% (neutropenia) |
Haj Mohammad, N (2014) [12] | 127 | Retrospective | 36% SCC | 50.4 Gy (28 Fx.) | Paclitaxel Carboplatin | 17.1 months (inoperable patients) 17.4 months (irresectable tumors) | 42% | 44% | 7% (leukopenia) |
Noronha, V (2016) [13] | 179 | Retrospective | 92.2% SCC | Mean dose 58.7 Gy in 32 Fx. | Paclitaxel Carboplatin | 19 months (1-year OS: 70%) | 32% | 15% | 49% (leukopenia) |
Honing, J (2014) [14] | 102 | Retrospective | 50% SCC | Median dose 50.4 Gy, daily dose 1.8–2 Gy | 1. Cisplatin 5-FU 2. Paclitaxel Carboplatin | 1. 16.1 months 2. 13.8 months | – | – | 1. 19% 2. 4% |
Herskovic, A (1992) [15] | 61 (combined treatment) | Phase 3 | 84% SCC | 50 Gy (25 Fx) | Cisplatin 5-FU | 12.5 months (1-year OS: 50%) | 43% | 22% (after one year) | 48% |
Minsky, BD (2002) [17] | 218 | Phase 3 | 86% SCC | 1. 50.4 Gy (28 Fx) 2. 64.8 Gy (36 Fx) | Cisplatin 5-FU | 1. 18.1 months 2. 13 months | 1. 55% 2. 50% | 1. 16% 2. 9% | – |
This study | 47 | Retrospective | 100% SCC | 1. Median dose 54 Gy (30 Fx.) 2. Median dose 59.4 Gy (33 Fx.) | 1. Cisplatin 5-FU 2. Paclitaxel Carboplatin | 1. 24.2 months (1-year OS: 72%) 2. Not reached after 18.2 months) (1-year OS 70%) | 1. 48% (36% after one year) 2. 36% (32% after one year) | 1. 20% (8% after one year) 2. 27% (18% after one year) | 1. 52% 2. 55% |